“If successful, we hope that treatments such as Aviptadil may change the chances of survival for these patients,” says Dr. Richard Lee, who is leading the trial at UCI. Carlos Puma for UCI Health
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave condition that even mechanical ventilation cannot improve. Aviptadil, which has a 20-year history of use in human clinical trials for lung ailments, will be employed in a phase 2b/3 clinical study of COVID-19 patients suffering from acute respiratory distress syndrome, a primary cause of coronavirus-induced death. Read more here >
